Analysis of multicatheter interstitial brachytherapy: Accelerated partial breast irradiation in a retrospective cohort of early-stage breast cancer patients

PURPOSE: To determine cardiac dose received by patients treated with high dose rate interstitial brachytherapy. Patients with early -stage, node negative breast cancer can be treated using multi -catheter interstitial brachytherapy accelerated partial breast irradiation (MIB-APBI), with the benefit of reduced treatment volumes and favorable toxicity. METHODS AND MATERIALS: We conducted a retrospective review of left -sided breast cancer patients treated using MIB-APBI at our institution since 2014. The mean heart dose (MHD) was calculated using the Oncentra 3.2 planning system. The minimum distance between the planning target volume (PTVeval) and heart contour was measured manually. FINDINGS: 81 patients were included. The upper outer quadrant was the most common site. The MHD was 97.8 cGy (EQD2a/b = 2) (range 22-229 cGy). MHD significantly correlated with the closest distance between PTVeval and heart contour (correlation coefficient -0.823, p < 0.001); size of PTVeval (cc) and quadrant location did not. CONCLUSIONS: Appropriately selected women with early -stage, low -risk, left -sided breast cancer who received MIB-APBI had acceptable MHD. There was a strong correlation between the distance of PTVeval and MHD. Quadrant breast tumor is in cannot be used as a surrogate for MHD in brachytherapy. Our findings contribute to the growing evidence of the utility and safety of MIB-APBI.